Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 5/20 | 0.49 |
| ▸ | AURKA | O14965 | 5/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | VNN1 | O95497 | 3/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | VCP | P55072 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1585596 | 0.76 | KLKB1 (0.51) | RPS6KB1AURKA | |
| SCHEMBL7083955 | 0.76 | KDM4E (0.48) | KMONR3C2 | |
| SCHEMBL26921026 | 0.74 | RPS6KB1 (0.60) | RPS6KB1AURKAAURKBVNN1NR3C2 | |
| SCHEMBL7732439 | 0.72 | KDR (0.55) | RPS6KB1AURKAAURKBVNN1KDR | |
| SCHEMBL5094134 | 0.71 | CAMKK2 (0.54) | RPS6KB1AURKAAURKBVNN1VCP | |
| SCHEMBL3109871 | 0.69 | RXFP1 (0.81) | KDR | |
| Hydrochloric Acid SCHEMBL448201 | 0.69 | KDR (0.65) | KDRPDPK1 | |
| SCHEMBL4683411 | 0.69 | RORB (0.66) | TACR1KMO | |
| SCHEMBL30272163 | 0.69 | RORB (0.66) | TACR1KMO | |
| SCHEMBL5093362 | 0.69 | VNN1 (0.55) | RPS6KB1AURKAAURKBVNN1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030032656-A1 | 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032656-A1 | 2-Amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | KDR, ERBB2, FLT1 | RPS6KB1 380/4885AURKA 1050/4885AURKB 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.